• 1
    Donegan W. L. Cancer and pregnancy. CA 1983; 33: 194214.
  • 2
    White T. T., White W. C. Breast cancer and pregnancy: report of 49 cases followed 5 years. Ann Surg 1956; 144: 38493.
  • 3
    Saceda M., Lippman M. E., Chambon P., Lindsey R. L., Ponglikitmongkol M., Puente M., et al. Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol Endocrinol 1988; 2: 115762.
  • 4
    Read L. D., Greene G. L., Katzenellenbogen B. S. Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormone, their antagonists, and growth factors. Mol Endocrinol 1989; 3: 295304.
  • 5
    Horwitz K. B., McGuire W. L. Nuclear mechanisms of estrogen action. J Biol Chem 1978; 25–3: 818591.
  • 6
    McGuire W. L., De La Garza M., Chamness G. C. Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res 1977; 37: 6379.
  • 7
    Powell B., Garola R. E., Chamness G. C., McGuire W. L. Measurement of progesterone receptor in human breast cancer biopsies. Cancer Res 1979; 39: 167882.
  • 8
    Dressler L. G., Seamer L. C., Owens M. A., Clark G. M., McGuire W. L. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 1988; 61: 4207.
  • 9
    Ciocca D. R., Bjercke R. J. Immunocytochemical techniques using monoclonal antibodies. In: LangoneJ. J., Van VunakisH., editors. Methods in enzymology: immunochemical techniques. vol 121. Miami: Academic Press, 1986: 56279.
  • 10
    Elias J. M., Margiotta M., Gaborc D. Sensitivity and detection efficiency of the peroxidase antiperoxidase (PAP), avidin-biotin peroxidase complex (ABC), and peroxidase-labeled avidin biotin (LAB) methods. Am J Clin Pathol 1989; 92: 627.
  • 11
    Greene G. L., Nolan C., Engler J. P., Jensen E. V. Monoclonal antibodies to human estrogen receptor. Proc Natl Acad Sci USA 1980; 77: 51159.
  • 12
    Greene G. L., Harris K., Bova R., Kinders R., Moore B., Nolan C. Purification of T47D human progesterone receptor and immunochemical characterization with monoclonal antibodies. Mol Endocrinol 1988; 2: 71426.
  • 13
    Press M. F., Greene G. L. Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor. Endocrinology 1988; 122: 116575.
  • 14
    Press M. F., Greene G. L. Immunocytochemical localization of estrogen and progesterone receptors. In: De LellisR. A., editor. Advances in immunohistochemistry. New York: Raven Press, 1988: 34161.
  • 15
    Poulsen H. S., Ozzello L., King W. J., Greene G. L. The use of monoclonal antibodies to estrogen receptors (ER) for immunoperoxidase detection of ER in paraffin sections of human breast cancer tissue. J Histochem Cytochem 1985; 33: 8792.
  • 16
    Andersen J., Orntoft T. F., Poulsen H. S. Immunohistochemical demonstration of estrogen receptors (ER) in formalin-fixed, paraffin-embedded human breast cancer tissue by use of a monoclonal antibody to ER. J Histochem Cytochem 1988; 36: 155360.
  • 17
    Adams D. J., Hajj H., Bitar K. G., Edwards D. P., McGuire W. L. Purification of an estrogen-regulated breast cancer protein by monoclonal antibody affinity chromatography. Endocrinology 1983; 113: 4157.
  • 18
    Ciocca D. R., Stati A. O., Amprino de Castro M. M. Colocalization of estrogen and progesterone receptors with an estrogen-regulated heat shock protein in paraffin sections of human breast and endometrial cancer tissue. Breast Cancer Res Treat 1990; 16: 24351.
  • 19
    Nunez A. M., Jakowlev S., Briand J. P., Gaire M., Krust A., Rio M. C., et al. Characterization of the estrogen-induced pS2 protein secreted by the human breast cancer cell line MCF-7. Endocrinology 1987; 121: 175965.
  • 20
    Foekens J. A., Rio M. C., Seguin P., van Putten W. L. J., Fauque J., Nap M., et al. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 1990; 50: 38327.
  • 21
    Tandon A. K., Clark G. M., Chamness G. C., Ullrich A., McGuire W. L. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7: 11208.
  • 22
    King R. M., Welch J. S., Martin J. K. Jr., Coulam C. B. Carcinoma of the breast associated with pregnancy. Surg Gynecol Obstet 1985; 160: 22832.
  • 23
    Holleb A. I., Farrow J. H. The relation of carcinoma of the breast and pregnancy in 283 patients. Surg Gynecol Obstet 1962; 115: 6571.
  • 24
    Nugent P., O'Connell T. X. Breast cancer and pregnancy. Arch Surg 1985; 120: 12214.
  • 25
    Pertschuk L. P., Kim D. S., Nayer K., Feldman J. G., Eisenberg K. B., Carter A. C., et al. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Cancer 1990; 66: 166370.
  • 26
    Parl F. F., Posey Y. F. Discrepancies of the biochemical and immunohistochemical estrogen receptor assays in breast cancer. Hum Pathol 1988; 19: 9606.
  • 27
    Edwards D. P., Adams D. J., McGuire W. L. Estradiol stimulates synthesis of a major intracellular protein in a human breast cancer cell line (MCF-7). Breast Cancer Res Treat 1981; 1: 20923.
  • 28
    Rio M. C., Bellocq J. P., Gairard B., Rasmussen U. B., Krust A., Koehl C., et al. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene erbB-2. Proc Natl Acad Sci USA 1987; 84: 92437.
  • 29
    Brown A. M. C., Jeltsch J-M., Roberts M., Chambon P. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci USA 1984; 81: 63448.
  • 30
    Adams D. J., McGuire W. L. Quantitative enzyme-linked immunosorbent assay for the estrogen-regulated Mr 24,000 protein in human breast tumors: correlation with estrogen and progesterone receptors. Cancer Res 1985; 45: 24459.
  • 31
    Gusterson B. A., Machin L. G., Gullick W. J., Gibbs N. M., Powles T. J., Elliott C., et al. c-erbB-2 expression in benign and malignant breast disease. Br J Cancer 1988; 58: 4537.
  • 32
    Barnes D. M., Lammie G. A., Millis R. R., Gullick W. L., Allen D. S., Altman D. G. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 1988; 58: 44852.
  • 33
    van de Vijver M. J., Peterse J. L., Mooi W. J., Wisman P., Lomans J., Dalesio O., et al. Neu-protein overexpression in breast cancer. N Engl J Med 1988; 319: 123945.
  • 34
    Paik S., Hazan R., Fisher E. R., Sass R. E., Fisher B., Redmond C., et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 10312.
  • 35
    McGuire W. L., Tandon A. K., Allred D. C., Chamness G. C., Clark G. M. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990; 82: 100615.
  • 36
    Osborne C. K., Yochmowitz M. G., Knight W. A. III, McGuire W. L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46: 28848.
  • 37
    Clark G. M., McGuire W. L., Hubay C. A., Pearson O. H., Marshall J. S. Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med 1983; 309: 13437.
  • 38
    Petrek J. A., Dukoff R., Rogatko A. Prognosis of pregnancy-associated breast cancer. Cancer 1991; 67: 86972.